• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Rapid Micro Biosystems Inc.

    7/11/25 3:22:46 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001853904
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    RAPID MICRO BIOSYSTEMS, INC.
    SEC File Number
    001-40592
    Address of Issuer
    25 HARTWELL AVENUE
    LEXINGTON
    MASSACHUSETTS
    02421
    Phone
    978-349-3200
    Name of Person for Whose Account the Securities are To Be Sold
    Spignesi Robert G. Jr.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    1187439498.863933217207/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A07/10/2025Restricted Stock VestingIssuerCheckbox not checked1187407/10/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Robert G. Spignesi
    25 Hartwell Avenue
    Lexington � MA � 02421
    Class A07/08/20251082438021.46
    Robert G. Spignesi
    25 Hartwell Avenue
    Lexington � MA � 02421
    Class A07/09/20251124739480.34
    Robert G. Spignesi
    25 Hartwell Avenue
    Lexington � MA � 02421
    Class A07/10/20251161739479.21

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    07/11/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert G. Spignesi

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RPID alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    8/9/2021$28.00Buy
    Stifel
    More analyst ratings

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on June 2, 2025, of (i) 160,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") and (ii) non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") as a material inducement to employment to a new employee. All such equity awards were made under the Company's Inducement Plan, as amended (the

      6/13/25 4:30:27 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

      LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an

      5/27/25 9:00:22 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      12/5/24 6:44:47 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      11/27/24 9:42:03 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      8/9/24 8:36:24 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

      KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

      2/12/25 7:09:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems downgraded by JP Morgan

      JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

      8/16/22 7:57:15 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Rapid Micro Biosystems with a new price target

      Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously

      3/7/22 8:37:27 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Financials

    Live finance-specific insights

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

      Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

      2/28/25 6:30:13 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Spignesi Robert G. Jr. converted options into 50,290 shares and sold $78,979 worth of shares (23,755 units at $3.32), increasing direct ownership by 3% to 970,550 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      7/15/25 4:37:20 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT AND CEO Spignesi Robert G. Jr. converted options into 75,433 shares and sold $116,976 worth of shares (33,688 units at $3.47), increasing direct ownership by 8% to 944,015 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      7/10/25 7:43:21 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Bika Dafni

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      5/27/25 8:31:14 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/24 10:04:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      1/22/24 5:28:26 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/23 4:17:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    SEC Filings

    See more
    • SEC Form 144 filed by Rapid Micro Biosystems Inc.

      144 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      7/11/25 3:22:46 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      6/17/25 5:30:29 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/23/25 4:21:49 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

      LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an

      5/27/25 9:00:22 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

      LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

      7/18/23 5:20:56 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

      LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

      5/4/23 4:30:10 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials